G ram-positive bacteria account for the majority of antibioticresistant strains encountered in U.S. hospitals and for 65% of nosocomial infections in U.S. hospitals in adults (1) and children (2) . Gram-positive bacterial infections are present in 50% of sepsis patients in the United States (3) and are the major cause of organ failure and mortality in sepsis (4) . Nevertheless, Grampositive bacteria lack an obvious endotoxin that can account for the systemic inflammatory response that accompanies sepsis. In contrast, the cell wall of Gram-negative bacteria contains LPS and is a potent inducer of proinflammatory cytokines. LPS alone can account for the systemic inflammatory response that accompanies Gramnegative sepsis, as animals challenged with LPS display many of the features of septic shock caused by Gram-negative bacteria (5) .
Peptidoglycan (PGN), a major cell wall component of Grampositive bacteria (6) , has been proposed as an endotoxin in Grampositive bacteria (7) . However, PGN has a checkered history in this regard; in vivo, rodents challenged with PGN alone showed minimal pathology relative to LPS challenge (8) (9) (10) (11) . On the other hand, early in vitro studies established that crude bacterial cell wall preparations of Gram-positive bacteria that contained PGN were able to stimulate proinflammatory cytokines from immune cells (12) . However, the in vitro studies were done before TLRs were found in mammals and before the discovery of the myriad of TLR agonists present in crude bacterial cell wall preparations. More recent studies showed that removal of known TLR agonists from cell wall preparations containing PGN caused PGN to lose apparent biologic activity (13, 14) . These findings suggested that the biologic activity of PGN found in earlier experiments was instead due to contaminating TLR agonists and PGN itself was rather innocuous toward immune cells.
The recent discovery of the cytoplasmic nucleotide oligomerization domain (NOD) receptors made the issue of PGN more complex. When expressed in HEK293 cells, NOD receptors detected dipeptides or tripeptides derived from polymeric PGN to activate NF-kB (15) (16) (17) (18) . In their natural state, NOD receptors are cytoplasmic and hence unable to recognize the extracellular polymeric PGN shed from bacteria. Given this conundrum, complex models have been proposed in which polymeric PGN was first shed from vegetative bacteria and depolymerized in human plasma into PGN monomers of dipeptides or tripeptides. The PGN monomers were proposed to be internalized by innate immune cells to stimulate a proinflammatory response via the cytoplasmic NOD receptors (19) (20) (21) (22) .
Our recent studies have established that highly purified polymeric PGN does indeed stimulate proinflammatory cytokine production in human innate immune cells and that the polymeric nature of PGN was an essential property for cytokine induction. PGN polymers but not monomers were efficient stimulators of innate immune cells, whereas PGN monomers only stimulated nonhematopoietic cell lines transfected with NOD receptors (23, 24) . In contrast to human innate immune cells, mouse macrophages showed a minimal response to PGN stimulation. The reasons for the species difference are not clear, although in part they may be explained by the fact that PGN binds poorly to mouse macrophages (24) . Our previous work also showed that unlike LPS, the PGN-induced proinflammatory response is not dependent on the stimulation of an extracellular receptor (24) . Instead, we showed that polymeric PGN binds to select immune cells through an unidentified extracellular receptor and stimulates cytokine production after receptor-mediated phagocytosis and lysosomal degradation to generate NOD ligands (24) . We found that human monocytes and neutrophils express the unknown extracellular receptor that initiates PGN phagocytosis (24) . T lymphocytes completely failed to bind PGN and so appear to lack the extracellular PGN receptor (24) .
Given the PGN binding data, we hypothesized that the IgG receptors (FcgRs) might constitute the unidentified PGN extracellular receptor. Cell-activating FcgRs such as FcgRIIa and FcgRIIIb are expressed on innate immune cells, whereas T cells do not express FcgRs (25) . Activating FcgRs are highly phagocytic and traffic their cargo to lysosomes for degradation (26) ; these receptor properties are needed for conferring to the cell the ability to respond to PGN (27) .
In support of the hypothesis, we show that PGN binding to and proinflammatory cytokine production by human innate immune cells requires human plasma, that IgG-depleted plasma does not support binding or cytokine production, and that adding back normal intact but not F(ab9) 2 human IgG restores the ability of the IgG-depleted plasma to support PGN binding and cytokine production. Normal human plasma from uninfected people contains IgG Abs that bind PGN; the Abs are present at a low titer in all tested healthy plasma samples. The PGN Abs are absent from mouse plasma and FCS. Lastly, HEK293 cells fail to bind or phagocytose PGN; however, transfection with cDNA encoding human FcgRIIa or FcgRIIIb, the FcgRs expressed on human innate immune cells, confers on HEK293 cells the ability to bind and internalize PGN, again in a human plasma-dependent manner. We conclude that FcgRs serve indirectly as extracellular PGN receptors that enable innate immune cells to respond to PGN and contribute to the inflammation attending Gram-positive bacterial infections. Our findings identify a novel mechanism by which Gram-positive organisms are able to cause significant human pathology.
Materials and Methods

Materials
Cy5 rabbit anti-human IgG, g-chain specific and Cy5 rabbit anti-human IgM, m-chain specific were purchased from Jackson ImmunoResearch (West Grove, PA). Allophycocyanin-conjugated Abs to human CD14 and CD16b were purchased from Invitrogen (Grand Island, NY). Biotinconjugated Ab to human FcgRI (mAb 10.1) (28) was purchased from Abcam (Cambridge, MA). Biotin-conjugated Ab to human FcgRII (mAb AT10) (29) was purchased from Novus Biologicals (Littleton, CO), and biotin-conjugated Ab to human FcgRIII (mAb MEM-154) (30) was purchased from GeneTex (Irvine, CA). Allophycocyanin-and Cy5-conjugated streptavidin was purchased from eBioscience (San Diego, CA). Plasmids containing human FcgRIIA and FcgRIIIB cDNA clone were obtained from Origene (Rockville, MD). Fugene6 Transfection Reagent was obtained from Roche Applied Science (Foster City, CA). Human IgG was purchased from Lampire Biological Laboratories (Pipersville, PA). Blood and blood products were purchased from the Oklahoma Blood Institute or obtained from local volunteers after securing informed and written consent. All work with human blood was approved by the institutional review board of the Oklahoma Medical Research Foundation.
Preparation of Bacillus anthracis and Staphylococcus aureus PGN
Bacillus anthracis and Staphylococcus aureus peptidoglycan was prepared as described before (24) . Vegetative bacteria were collected after overnight culture and boiled in 8% NaDodSO 4 (SDS) in water. After washing in endotoxin-free water, the pellet was treated with DNase I and RNase A to eliminate nucleic acids. The sample was boiled again in 4% SDS, extracted with 2 M NaCl, and digested overnight with 48% hydrofluoric acid to remove lipoteichoic acid and teichoic acids (31) . The product was digested twice with proteinase K and reextracted with 6 M guanidine HCl. The final product was washed with endotoxin-free water and sonicated at 4 W for 10 min to cause it to remain in suspension. No TLR2 agonist or endotoxin was detected in the final product.
To label PGN with FITC or biotin, PGN was incubated with FITC and/or biotin N-hydroxysuccinimide ester in a 1:2 ratio (w/w) for 4 h at room temperature or overnight at 4˚C. The reaction was stopped by adding 1 M Tris (pH 8.0), and PGN was then washed in water.
Preparation of IgG F(ab9) 2 IgG and IgG-depleted plasma Fresh human plasma was passed over a protein A-sepharose column, and the bound IgG was eluted with sodium acetate (pH 2.5). The plasma was confirmed to be IgG free by Western blot for human IgH. The total protein of the IgG-depleted plasma was restored to its original concentration by adding human albumin in sterile PBS. The eluted IgG was concentrated and dialyzed against TBS or digested with pepsin at a 1:20 w/w ratio for 8 h at 37˚C. The digestion reaction was neutralized with 1 M Tris (pH 8.0) and passed a second time over protein A-sepharose. The nonbinding fraction was concentrated, dialyzed against TBS, and stored at 220˚C. For experiments in which the IgG was used in cytokine measurements, the purified intact IgG was passed thrice over 3 ml of polymyxin B-agarose (Sigma-Aldrich, St. Louis, MO) column to minimize endotoxin contamination and thus lower the background cytokine production.
Culture of peripheral blood
Heparinized peripheral blood was obtained from healthy volunteers according to the venipuncture protocol approved by the Oklahoma Medical Research Foundation internal review board. For measurement of PGN binding, PBMCs were prepared by centrifuging on Ficoll-Hypaque (SigmaAldrich) gradients as described (24) . The bottom layer containing neutrophils and RBCs was treated with 155 mM NH 4 Cl, 1 mM EDTA, 10 mM KHCO 3 (pH 7.4) to lyse the RBCs; 70-75% of the remaining cells expressed the neutrophil marker CD16b and were used as neutrophils without further purification. Contaminating lymphocytes and RBCs were gated out by forward and side scatter, and only CD16b-expressing cells were analyzed. When plasma was added, we used autologous or heterologous plasma with identical results; the plasma was always from a single individual and never pooled. When FCS was added, it was heat inactivated at 56˚C for 30 min. For measurements of cytokine production, whole blood was washed three times with PBS to remove plasma. The blood cells were reconstituted with PBS to their original volume and then diluted with two volumes of DMEM. The cells were cultured with added human plasma, FCS, IgG, or stimulants as described in the Results. Brefeldin A (3 mg/ml) was added to prevent cytokine secretion and the cells were processed as described previously (24, 27) .
Flow cytometric analysis
The detection of PGN binding to human cells by flow cytometry using FACSCalibur was performed as described previously (24) . Briefly, 1-2 3 10 6 PBMCs or neutrophils were treated with FITC-labeled PGN (10 mg/ ml) in 0.5-1 ml for 30 min at ambient temperature in the presence or absence of plasma from a single individual. After washing in PBS, the cells were incubated with fluorochrome-labeled cell surface Abs for 30 min on ice to identify particular cell populations (anti-CD14 for monocytes and anti-CD16b for neutrophils). Cells positive for the identifying surface marker and PGN-FITC or cytoplasmic cytokines were quantitated by flow cytometric analysis; a total 200,000 cells were analyzed in each experiment. Ab to peptidoglycan was detected using a modified flow cytometry assay. Peptidoglycan was incubated in PBS-diluted plasma samples (0.2-1 ml) obtained from a single individual for 30 min on ice, washed with PBS, and stained with Cy5-anti-IgG that was g-chain and species-specific. Ten thousand PGN particles were quantitated for IgG binding.
Transfections
HEK293 cells were grown in DMEM supplemented with 10% FBS at 37˚C and 5% CO 2 . The day before transfection, HEK293 cells were subcultured to allow cell confluency to reach 50% for transfection. Fugene reagent (Promega, Madison, WI) and DNA were mixed at a 3:1 ratio in serum-free DMEM, and the mixture was added to the cells. HEK293 cells were cultured for 48 h at 37˚C and 5% CO 2 before analysis of PGN binding as described above. For PGN phagocytosis, the transfectants were incubated in suspension in DMEM containing (or not containing) 10% human plasma with 10 mg/ml PGN doubly-labeled with FITC and biotin. After 30 min, the cells were washed with PBS and stained with allophycocyanin-labeled streptavidin for 30 min at 4˚C. The cells were placed on polylysine-coated coverslips and viewed with a Zeiss LSM 510 confocal microscope using 363 and 3100 oil objectives.
Microscopy
Unsonicated PGN-FITC was incubated with human or mouse plasma for 30 min on ice. The material was centrifuged at 2000 3 g and washed three times with PBS. The washed PGN-FITC was stained with Cy5-labeled anti-Ig reagent (human-or mouse-specific) or anti-human albumin. The PGN was mounted on a polylysine-coated coverslip and observed with a Zeiss LSM 510 confocal microscope using 363 and 3100 oil objectives.
Statistical analysis
All statistical analyses were performed with GraphPad Prism software. Statistical significance was determined using a t test, and a p value of ,0.05 was considered statistically significant.
Results
PGN binding to human monocytes and neutrophils requires human plasma
Using flow cytometry to assess B. anthracis-derived PGN binding to immune cells, we previously found that CD14 + monocytes and CD16b + neutrophils bind PGN (24) . In these experiments, we noticed that PGN binding was inefficient when using traditional cell culture media containing FCS, but robust when using diluted human blood. The observation raised the possibility that PGN binding required human plasma. To test this issue, we washed purified neutrophils or PBMCs as a source of human monocytes with PBS to remove plasma. The cells were then reconstituted with either human plasma at 10% v/v or with PBS and incubated with fluorescein-labeled PGN (PGN-FITC). Abs to CD14 and CD16b were used to label monocytes and neutrophils, respectively, and PGN binding was analyzed by flow cytometry. Without plasma, PGN bound only 19% of monocytes ( Fig. 1A ) and 14% of neutrophils (Fig. 1C ). For both monocytes (Fig. 1B ) and neutrophils ( Fig. 1D ), PGN binding increased to ∼70-80% in the presence of 10% plasma. PGN-FITC binding to monocytes and neutrophils increased with time ( Fig. 1E ) and was not supported at concentrations of plasma ,10% (Fig. 1F) . Similar results were obtained using PGN derived from S. aureus (data not shown). These data indicate that monocytes and neutrophils require human plasma for recognition of PGN derived from Gram-positive bacteria.
Human IgG is a necessary and sufficient plasma component to support PGN binding to monocytes and neutrophils
Because the cell types that bind PGN express high levels of IgG receptors, we hypothesized that IgG in plasma facilitates PGN binding. To test this hypothesis, we prepared IgG-depleted plasma by passing fresh human plasma over protein A-agarose. The IgGdepleted plasma was reconstituted to its original volume and protein concentration by adding human albumin in PBS. The IgGdepleted or complete human plasma was then used at 10% v/v for binding assays using B. anthracis-or S. aureus-derived PGNs and PBMCs or purified neutrophils. For both monocytes ( Fig. 2A) and neutrophils (Fig. 2B) , PGN binding was significantly reduced when the binding assay was done in the presence of IgG-depleted plasma (p , 0.01). Reconstituting the IgG-depleted plasma with normal intact human IgG restored PGN binding for both cell types, but F(ab9) 2 fragments of human IgG did not support PGN binding. To test whether human IgG was sufficient for PGN binding to immune cells, we incubated labeled PGN derived from B. anthracis or S. aureus with blood cells in PBS. We added human albumin, intact or F(ab9) 2 fragments of human IgG, or intact mouse IgG and measured PGN binding to monocytes and neutrophils by flow cytometry. Intact human but not mouse IgG was sufficient to allow PGN binding, and F(ab9) 2 fragments of human IgG failed to support PGN binding (Fig. 2C, 2D ). These data indicate that the IgG in human plasma is both necessary and sufficient to support PGN binding to blood cells and that the Fc portion of IgG is critical for this function.
Human plasma contains IgG against PGN
Because of the importance of IgG in supporting PGN binding to human immune cells, we used fluorescence microscopy to determine whether human plasma from normal healthy individuals contains Abs against PGN. We used larger, unsonicated PGN for this experiment to facilitate its visualization by microscopy. First, human plasma from a single individual was incubated with unsonicated PGN-FITC for 30 min 4˚C. After washing, the PGN was incubated with Cy5-labeled anti-human IgG or IgM (both H chain-specific) and then viewed by confocal microscopy. Based on PGN staining with Cy5-labeled Abs to human Ig, we found that this sample of human plasma contained IgG but not IgM that recognized PGN (Fig. 3A, 3B ). As albumin is another prominent plasma protein, we stained plasma-incubated PGN with antialbumin to test whether the IgG binding was specific or whether PGN nonspecifically bound protein in the plasma sample. Staining of the plasma-incubated PGN for human albumin was negative, and the Cy5-anti-human IgG Abs did not stain PGN that had not been incubated with plasma (data not shown). When PGN was incubated with mouse plasma and stained with Cy5-anti-mouse IgG, no mouse IgG was detected (Fig. 3C ). This finding is con- sistent with our previous findings that mouse bone marrow-derived macrophages respond minimally to PGN and bind PGN poorly, whereas human cells respond vigorously and bind well (24) .
To confirm and extend these results, we next characterized anti-PGN IgG in human plasma from 30 healthy individuals. Because PGN prepared from vegetative bacteria is particulate (24) , IgG binding to PGN could be assessed by flow cytometry. We used sonicated B. anthracis PGN, which had an average particle size of ∼1.8 mm based on forward scatter properties as compared with latex beads of known particle size (data not shown). Unlabeled PGN was incubated with human plasma, washed, and stained with Cy5-labeled anti-human IgG. The titration for a single representative individual is shown in Fig. 3D -H and reveals that maximal fluorescence for PGN-bound human IgG was obtained at a 1:10 dilution of the human plasma, consistent with the data in Fig. 1 . Each of the 30 plasma samples from healthy individuals showed human IgG binding to PGN, although some samples had relatively lower amounts of PGN Abs (Fig. 3I) . These data show that anti-PGN IgG is present in plasma from healthy human donors at a low concentration.
PGN-induced proinflammatory cytokine production requires human IgG
Our previous work established that PGN binding to an extracellular receptor is the first step in PGN-triggered proinflammatory cytokine production (24) . Following binding, PGN is phagocytosed and digested in lysosomes, and the digestion products are recognized by cytoplasmic receptors (27) . It follows that induction of proinflammatory cytokines by human innate immune cells should also require human plasma or human IgG, or both. To test this prediction, we determined how the ubiquitous anti-PGN IgG affected the production of TNF-a and IL-8, the predominant cytokines made by monocytes and neutrophils, respectively (23) . We were unable to use the IgG-depleted plasma above because it was invariably contaminated with endotoxin, making it unsuitable for cytokine production assays. In lieu of IgG-depleted human plasma, we made use of FCS, which had minimal PGN Abs that were present in all tested human plasma (data not shown). Endotoxin was removed from the protein A-purified human IgG by passing the IgG over polymyxin B columns until the purified IgG failed to stimulate cytokine production in human cells by itself. Monocytes or neutrophils were incubated with 10% human plasma, 10% FCS, or 10% FCS containing 100 mg/ml intact human IgG. Under each of these conditions, treatment with the positive control LPS elicited a strong cytokine response from both monocytes and neutrophils relative to unstimulated cultures (Fig.  4) . As expected, PGN elicited a strong cytokine response in the presence of human plasma but not in FCS, which lacks the anti-PGN IgG. When FCS was supplemented with 100 mg/ml human IgG, PGN was able to stimulate the IL-8 response in neutrophils (55% positive cells versus 8% positive in FCS; n = 3; p , 0.05), and the TNF-a responses in monocytes (53% positive cells versus 10% positive in FCS; n = 3; p , 0.05) were increased in FCS cultures when supplemented with 100 mg/ml human IgG, although not to the same levels as observed in human plasma (Fig. 4) . This may be because FCS, even when supplemented with human IgG, supports PGN binding to a slightly lower level than with whole human serum, although the difference was not statistically different (data not shown). There was no change in cell viability when cultured in FCS or human plasma.
To test further whether the PGN Abs in normal plasma are involved in PGN binding and cytokine induction, we compared PGN binding and PGN-triggered cytokine production in complete human plasma depleted of anti-PGN IgG. One milliliter of normal human plasma was incubated with 300 mg PGN for 1 h, and PGN was removed from the sample by centrifugation. The depletion was repeated once more, and the depleted plasma was tested for its ability to support PGN binding and cytokine production. We found that plasma depleted of PGN Abs did not support PGN binding to monocytes or neutrophils (Fig. 5A) , nor did it support cytokine production from these cells (Fig. 5B) . Adding back normal human IgG restored both responses. The data show that the anti-PGN IgG in human plasma is necessary for both PGN binding and cytokine production.
Because the components of PGN are somewhat conserved among bacterial species (32), we hypothesized that Abs that recognize Bacillus-derived PGN derived might affect the ability of immune cells to bind PGN derived from Staphylococcus. To test this possibility, we treated the plasma of five healthy individuals with B. anthracis-derived PGN to deplete Abs that recognize Bacillus-derived PGN. To confirm that IgG was removed from the human plasma by PGN adsorption, protein bound to Bacillus PGN was eluted with SDS sample buffer and analyzed for IgG by Western blotting (Fig. 5C, inset) . We then used the depleted plasma at 10% in an immune cell binding assay using S. aureusderived PGN. Using flow cytometry, we found that the plasma samples depleted of Abs that recognize Bacillus PGN had a reduced ability to support immune cell binding of Staphylococcus PGN (Fig. 5C) . Next, to test whether the plasma samples depleted of anti-Bacillus PGN Abs still had remaining Abs to PGN derived from Staphylococcus, we used flow cytometry to assess binding of unlabeled particulate PGN to IgG in plasma. IgG binding was detected with Cy5-labeled anti-human IgG. As in Fig. 3I , the individuals varied in their titer of anti-PGN as shown in Fig. 3 , and this natural variation is especially obvious when the mean fluorescence intensity of human IgG bound to PGN was plotted on a linear scale (Fig. 5D) . Despite the variation in initial titer, all individual plasma samples showed a decrease in anti-Staphylococcus PGN Abs after preadsorption with Bacillus PGN (Fig. 5D) . The data show that normal human plasma contains Abs to PGN derived from more than one bacterial species, and that there is cross-reactivity of a fraction of those Abs toward the PGN of different bacterial species.
FcgRIII on neutrophils and FcgRII on monocytes are internalized with same kinetics as PGN
Because innate immune cells only bound PGN in the presence of IgG, we hypothesized that PGN is first opsonized by IgG and then recognized and phagocytosed by the IgG receptors (FcgRI-III) expressed on innate immune cells. To address this hypothesis, FIGURE 4 . IgG is required for PGN-triggered cytokine production by innate immune cells. Whole diluted blood was washed free of plasma and reconstituted with 10% plasma, 10% FCS, or FCS with 100 mg/ml intact human IgG. The cells were incubated with 10 mg/ml unlabeled PGN for 6 h and processed for staining to detect intracellular cytokines. Monocytes (A) were stained for cytoplasmic TNF-a, and neutrophils (B) were stained for cytoplasmic IL-8. Both cell types were gated as described in Fig. 2 . The data are the average and SE of cells and plasma from four individuals. *p , 0.05, **p , 0.01. we first used flow cytometry to analyze the expression levels of these IgG receptors on innate immune cells. Both monocytes and neutrophils expressed very low levels of FcgRI, detected by the mAb 10.1 (Fig. 6A) . Whereas FcgRII (detected by mAb AT10) was the predominant monocyte IgG receptor and FcgRIII (detected by mAb MEM-154) was the predominant neutrophil IgG receptor, both cell types expressed both of these receptors.
We hypothesized that the Fc receptors would be internalized along with their IgG-bound cargo. To test this possibility, we incubated DMEM-diluted (1:3) whole blood with unlabeled PGN at 37˚C. Cells were analyzed at various times by flow cytometry for the surface expression level of the predominant IgG receptor: FcgRII in monocytes and FcgRIII in neutrophils. As a control, we also analyzed the expression of other monocyte and neutrophil surface receptors TLR4 and HLA class I. For both monocytes (Fig. 6B) and neutrophils (Fig. 6C) , expression of the predominant IgG receptor decreased with time of incubation with PGN. The average FcgR loss using samples from five to seven individuals are shown in Fig. 6D and 6E . The unstimulated level of expression of FcgRII on monocytes varied between individuals (Fig. 6D) and thus the loss of FcgRII on monocytes that accompanied PGN phagocytosis did not reach statistical significance until 90 min of incubation. Likewise, the FcgRIII loss in neutrophils was statistically significant only at later time points. Although the expression level of FcgRII and FcgRIII decreased upon PGN incubation, other monocyte and neutrophil surface receptors (TLR4 and HLA class I) were maintained at 100% of their initial level after 90 min of incubation with PGN (Fig. 6F) . Likewise, surface FcgR expression on cells treated with PGN did not occur decrease when the cells were treated with cytochalasin D, a defining criterion for phagocytosis (Ref. 33 and data not shown), and indicate that receptor shedding or proteolysis does not account for the loss in FcgR expression. These findings are consistent with the hypothesis that the FcgRs mediate the internalization of IgG-opsonized PGN.
Transfection with FcgRs renders HEK293 cells competent to bind and phagocytose PGN
To confirm that FcgRs have a role in receptor-mediated binding of PGN, we tested whether a nonhematopoietic cell could bind PGN in the presence of human plasma if the cells expressed FcgR. For this experiment, HEK293 cells were transfected with a control vector or with a vector encoding either human FcgRIIa or FcgRIIIb. The transfectants were incubated with PGN-FITC in the presence or absence of 10% human plasma for analysis of PGN binding. Untransfected HEK293 cells failed to bind PGN-FITC (Fig. 7A) , and FcgR-transfected HEK293 cells failed to bind PGN-FITC in the absence of plasma (Fig. 7B ). The FcgRIIA (Fig.  7C) or FcgRIIIB (not shown) transfectants were arbitrarily gated based on their FcgR expression levels into low, medium, or high expressing cells, and the percentage of PGN-FITC bound to each fraction was measured. For both FcgRIIa (Fig. 7D-F HEK293 cells phagocytose particles once transfected with a phagocytic receptor such as TLR4 (34) . We tested the possibility that FcgR transfection into HEK293 cells would allow the cells to internalize PGN in the presence of human plasma. For these experiments, we used the human FcgRIIA gene because, unlike other FcgRs, the protein contains an endogenous signaling domain and does not rely on the common g-chain (35) . We also used PGN doubly labeled with biotin and FITC. FcgRIIA-transfected HEK293 cells were incubated with the doubly labeled PGN at 4˚C to prevent phagocytosis or at 37˚C to permit phagocytosis (24) . We used cytochalasin D-treated cells as an additional control, because our earlier work showed that cytochalasin D blocks PGN phagocytosis (24) . After incubation, the cells were treated with Cy5-labeled streptavidin to detect extracellular PGN. With this protocol, extracellular PGN particles would show fluorescence from both FITC (green) and Cy5-streptavidin (red). In contrast, the intracellular phagocytosed PGN particles would appear only green as they would be inaccessible to the Cy5-streptavidin reagent. We found that FcgRIIA-transfected HEK293 cells kept at 4˚C (Fig. 7G) or treated with cytochalasin D (Fig. 7H) showed only extracellular PGN particles that were labeled both green and red. Thus, as expected, the reduced temperature and the inhibitor of actin reorganization prevented PGN phagocytosis. FcgRIIAtransfected HEK293 cells incubated at 37˚C showed the phagocytosed PGN-FITC, some of which was labeled with Cy5-streptavidin (marked with white arrowheads in Fig. 7I ) and are thus extracellular. The PGN particles that are only green indicate those that have been internalized. Counting 100 cells and noting the number that had taken up at least one particle, we found that ∼60% of the FcgR-transfected HEK293 cells phagocytosed PGN. This number is consistent with the overall transfection efficiency of the cells, which was also 60%. Phagocytosis of PGN into FcgRIIA-transfected HEK293 was plasma and IgG dependent (data not shown). These data establish that transfection of FcgRII into HEK293 cells makes the transfectants capable of phagocytosing PGN particles, which is consistent with the hypothesis that FcgRs have a major role in the internalization and PGN-induced inflammatory cytokine production in hematopoietic cells.
Discussion
Although infectious disease caused by Gram-positive bacteria is an important human health concern, a pathogenic mechanism by which these bacteria cause systemic inflammation is lacking. Previously, we showed that PGN has the capacity to induce proinflammatory cytokines from human but not mouse innate immune cells (24) . PGN is a major component of all bacterial cell walls and is especially prominent in Gram-positive bacteria. Therefore, PGN could contribute to the inflammation that occurs during Gram-positive sepsis. Despite the fact that PGN is a potent inducer of proinflammatory cytokines, it is not known how PGN is recognized by the human immune system. In this study, we report that IgG within human plasma supports PGN binding to monocytes and neutrophils and is required for proinflammatory cytokine production. We also show that plasma from normal, healthy human donors contains IgG that binds and opsonizes PGN for recognition by the IgG receptors on monocytes and neutrophils, FcgRII and FcgRIII. Lastly, transfection of HEK293 cells with cDNA encoding FcgRIIa or FcgRIIIb is sufficient to support PGN binding, and transfection of FcgRIIA alone is sufficient for phagocytosis in HEK293 cells.
Based on these data, we propose a model in which polymeric PGN is shed by growing bacteria and opsonized by IgG, allowing indirect detection by innate immune cells via FcgRs. After receptor engagement, PGN is internalized, trafficked to lysosomes, and degraded (27) . The intracellular PGN monomers (the products of lysosomal degradation) are recognized by intracellular NOD-like receptors to stimulate cytokine production. Hence, the anti-PGN IgG in humans acts to support proinflammatory cytokine production. This new model elucidates a novel mechanism contributing to the pathology caused by Gram-positive bacterial infections in humans.
Over 30 years ago, a survey of sera from 170 individuals using PGN present in the cell wall fraction of S. aureus showed that all people have IgG Abs to PGN (36) . It is difficult to exclude the possibility that the IgG Abs were directed against the many TLR agonists present in bacterial cell walls that have been discovered since that time. The previous work showed that although present in all normal controls at low titer, anti-PGN reactivity was higher in patients with an active S. aureus infection. We note that the chemical structure of PGN in Gram-positive bacteria is fairly conserved. All PGNs are b-linked polymers (1-4) of Nacetylglucosamine and N-acetylmuramic acid. Chains of the disaccharide polymers are linked with a short 4-aa stem peptide consisting of two alanine residues, a glutamine, isoglutamine, or glutamic acid residue, and a basic amino acid, which is diaminopimelic acid in Bacillus and lysine in Staphylococcus and Streptococcus. Staphylococcus PGN also has an additional bridge of five glycine residues linking the stem peptides. Given the relatively conserved structure, it is conceivable that a B lymphocyte memory response to Bacillus PGN could be triggered by a subsequent staphylococcal infection. Indeed, we found that plasma depleted of anti-Bacillus PGN Abs was less able to support binding of Staphylococcus PGN, which is consistent with the hypothesis. We have not studied the source of the anti-PGN IgG in humans, but we speculate that anti-PGN Abs arise from casual contact with nonpathogenic forms of Gram-positive bacteria or may reflect a historical infection with a pathogenic Gram-positive organism.
Interestingly, laboratory mice, which are housed in barrier facilities, fed autoclaved food and sterilized water, and otherwise kept in highly sterile environments, show a minimal response to PGN. Unlike in human innate immune cells, we previously showed that mouse cells display a relatively poor response to PGN in vitro (24) and others have reported that in vivo challenge with PGN alone produces only minor pathology in rodents (8, 10, 11) . According to our model, the poor response of laboratory animals to PGN could be explained by an absence of anti-PGN IgG, which would reduce the ability of PGN to bind immune cells and subsequently elicit proinflammatory cytokines. Indeed, we found that mice lack anti-PGN IgG. The data are consistent with our central conclusion that the presence of anti-PGN IgG is causally related to PGN-triggered production of cytokines and can contribute to the pathology accompanying Gram-positive infections. It is unfortu- nate that human IgG has a 10-fold lower affinity for mouse Fcg receptors (37) , otherwise the model could be further tested in vitro and in vivo with mouse macrophages and human IgG that contains PGN Abs. It has been established that mice form high-affinity IgG to PGN following PGN vaccinations, and these Abs protect the mice from Gram-positive infections (38) .
Although our data strongly implicate a role for FcgRIIa and FcgRIIIb in responding to PGN-anti-PGN immune complexes in monocytes and neutrophils, the findings do not exclude a contribution by other Ig receptors. We interpret the data to indicate that any Ig receptor can engage the PGN-containing immune complexes. Some individuals may have circulating IgA or IgE to PGN, and immune complexes formed with these Igs would conceivably bind to Ig receptors that recognize those Ig isotypes. In addition, it is likely that phagocytosis of the PGN-anti-PGN immune complexes is regulated by the inhibitory FcgRIIb, which is known to be expressed on the surface of monocytes and neutrophils (39) .
We hypothesize other surface proteins of innate immune cells, besides FcgR, can participate in PGN phagocytosis. For example, even in the absence of serum we found that up to 30% of innate immune cells can bind PGN. There is good evidence that CD14 acts as an extracellular PGN receptor (40) . CD14 normally cooperates with other surface membrane proteins to elevate its phagocytic proficiency and to promote production of cytokines: TLR4 in the case of LPS (34) and, by our findings, FcgRII and FcgRIII in the case of PGN. However, by itself CD14 is relatively poor in promoting phagocytosis, and cells do not produce proinflammatory cytokines following CD14 stimulation alone (41) . Therefore, CD14 might account for the low level binding we found in the absence of human plasma, which was insufficient to support cytokine production. We propose that the complement receptors may also be involved in PGN recognition because heatinactivation of plasma reduces the ability of PGN to bind and elicit cytokines from human cells by ∼30%.
It is perplexing that PGN would require the extra step of phagocytosis for production of proinflammatory cytokines when simple FcgR binding should be sufficient (42) . The explanation could be that too few FcgRs are engaged when PGN is recognized, a consequence of the low titer of PGN Abs. Recent experiments showed that mouse macrophages phagocytose particles coated with 10-100-fold fewer IgG molecules (and hence fewer FcgR bound) than were needed to trigger cytokine production (43) . The low titer of PGN Abs might ensure that PGN particles are phagocytosed but fail to elicit cytokines until PGN lysosomal digestion and NOD stimulation.
Although the PGN Abs in people may prevent an infection from becoming established, they also could contribute to the pathology accompany overwhelming infections by stimulating massive cytokine production. In the case of B. anthracis acquired by an inhalation route, patients show a remarkable bacteremia with 1 3 10 8 organisms per milliliter of blood in infected individuals (44) . It is difficult to say how much PGN is present in an infection of that level. An estimate in S. aureus found 1.25 mg PGN per 1 3 10 10 vegetative bacteria (45) . However, in addition to the PGN associated with vegetative bacteria, the B. anthracis-related species Bacillus subtilis was found to release 50% of its cell wall PGN with each generation (46) , and we similarly found shed PGN in growing B. anthracis cultures (24) . The released material is all polymeric and therefore capable of stimulating innate immune cells (46) . Assuming a blood volume of 5 l and a generational time of 20 min, a patient with such a bacteremia could be exposed to nearly 100 mg of PGN every 20 min. If the pathology during Gram-positive infections were at least in part caused by cytokine production from innate immune cells, the presence of IgG against PGN would facilitate systemic inflammatory response syndrome in Gram-positive infections. Therefore, in addition to uncovering the extracellular PGN receptor, our results have identified a novel means through which Gram-positive organisms can cause systemic inflammation in humans.
